» Articles » PMID: 36451356

NigraNet: An Automatic Framework to Assess Nigral Neuromelanin Content in Early Parkinson's Disease Using Convolutional Neural Network

Overview
Journal Neuroimage Clin
Publisher Elsevier
Specialties Neurology
Radiology
Date 2022 Dec 1
PMID 36451356
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parkinson's disease (PD) demonstrates neurodegenerative changes in the substantia nigra pars compacta (SNc) using neuromelanin-sensitive (NM)-MRI. As SNc manual segmentation is prone to substantial inter-individual variability across raters, development of a robust automatic segmentation framework is necessary to facilitate nigral neuromelanin quantification. Artificial intelligence (AI) is gaining traction in the neuroimaging community for automated brain region segmentation tasks using MRI.

Objective: Developing and validating AI-based NigraNet, a fully automatic SNc segmentation framework allowing nigral neuromelanin quantification in patients with PD using NM-MRI.

Methods: We prospectively included 199 participants comprising 144 early-stage idiopathic PD patients (disease duration = 1.5 ± 1.0 years) and 55 healthy volunteers (HV) scanned using a 3 Tesla MRI including whole brain T1-weighted anatomical imaging and NM-MRI. The regions of interest (ROI) were delineated in all participants automatically using NigraNet, a modified U-net, and compared to manual segmentations performed by two experienced raters. The SNc volumes (Vol), volumes corrected by total intracranial volume (C), normalized signal intensity (NSI) and contrast-to-noise ratio (CNR) were computed. One-way GLM-ANCOVA was performed while adjusting for age and sex as covariates. Diagnostic performance measurement was assessed using the receiver operating characteristic (ROC) analysis. Inter and intra-observer variability were estimated using Dice similarity coefficient (DSC). The agreements between methods were tested using intraclass correlation coefficient (ICC) based on a mean-rating, two-way, mixed-effects model estimates for absolute agreement. Cronbach's alpha and Bland-Altman plots were estimated to assess inter-method consistency.

Results: Using both methods, Vol, C, NSI and CNR measurements differed between PD and HV with an effect of sex for C and CNR. ICC values between the methods demonstrated optimal agreement for C and CNR (ICC > 0.9) and high reproducibility (DSC: 0.80) was also obtained. The SNc measurements also showed good to excellent consistency values (Cronbach's alpha > 0.87). Bland-Altman plots of agreement demonstrated no association of SNc ROI measurement differences between the methods and ROI average measurements while confirming that 95 % of the data points were ranging between the limits of mean difference (d ± 1.96xSD). Percentage changes between PD and HV were -27.4 % and -17.7 % for Vol, -30.0 % and -22.2 % for C, -15.8 % and -14.4 % for NSI, -17.1 % and -16.0 % for CNR for automatic and manual measurements respectively. Using automatic method, in the entire dataset, we obtained the areas under the ROC curve (AUC) of 0.83 for Vol, 0.85 for C, 0.79 for NSI and 0.77 for CNR whereas in the training dataset of 0.96 for Vol, 0.95 for C, 0.85 for NSI and 0.85 for CNR. Disease duration correlated negatively with NSI of the patients for both the automatic and manual measurements.

Conclusions: We presented an AI-based NigraNet framework that utilizes a small MRI training dataset to fully automatize the SNc segmentation procedure with an increased precision and more reproducible results. Considering the consistency, accuracy and speed of our approach, this study could be a crucial step towards the implementation of a time-saving non-rater dependent fully automatic method for studying neuromelanin changes in clinical settings and large-scale neuroimaging studies.

Citing Articles

Classification of Parkinson's disease by deep learning on midbrain MRI.

Welton T, Hartono S, Lee W, Teh P, Hou W, Chen R Front Aging Neurosci. 2024; 16:1425095.

PMID: 39228827 PMC: 11369979. DOI: 10.3389/fnagi.2024.1425095.


Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry.

Wengler K, Trujillo P, Cassidy C, Horga G Neuropsychopharmacology. 2024; 50(1):137-152.

PMID: 39160355 PMC: 11526017. DOI: 10.1038/s41386-024-01934-y.


Regional nigral neuromelanin degeneration in asymptomatic leucine-rich repeat kinase 2 gene carrier using MRI.

Gao L, Gaurav R, Ziegner P, Ma J, Sun J, Chen J Sci Rep. 2024; 14(1):10621.

PMID: 38729969 PMC: 11087650. DOI: 10.1038/s41598-024-59074-8.


An automatic interpretable deep learning pipeline for accurate Parkinson's disease diagnosis using quantitative susceptibility mapping and T1-weighted images.

Wang Y, He N, Zhang C, Zhang Y, Wang C, Huang P Hum Brain Mapp. 2023; 44(12):4426-4438.

PMID: 37335041 PMC: 10365226. DOI: 10.1002/hbm.26399.

References
1.
Prasad S, Stezin A, Lenka A, George L, Saini J, Yadav R . Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. Eur J Neurol. 2018; 25(4):680-686. DOI: 10.1111/ene.13573. View

2.
Blazejewska A, Schwarz S, Pitiot A, Stephenson M, Lowe J, Bajaj N . Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology. 2013; 81(6):534-40. PMC: 3775686. DOI: 10.1212/WNL.0b013e31829e6fd2. View

3.
Xing Y, Sapuan A, Martin-Bastida A, Naidu S, Tench C, Evans J . Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis. Mov Disord. 2022; 37(5):1028-1039. PMC: 9303322. DOI: 10.1002/mds.28934. View

4.
Carballo-Carbajal I, Laguna A, Romero-Gimenez J, Cuadros T, Bove J, Martinez-Vicente M . Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis. Nat Commun. 2019; 10(1):973. PMC: 6405777. DOI: 10.1038/s41467-019-08858-y. View

5.
Cheng H, Ulane C, Burke R . Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010; 67(6):715-25. PMC: 2918373. DOI: 10.1002/ana.21995. View